Federal Circuit Rules for Pfizer in Suit Vs. Ranbaxy

Law360, New York (December 29, 2003, 12:00 AM EST) -- The Court of Appeals for the Federal Circuit last week upheld a preliminary injunction barring India’s Ranbaxy Pharmaceuticals from marketing a generic version of Pfizer's Vantin antibiotic, Pfizer said.

The court affirmed a lower court ruling by the U.S. District Court of New Jersey. In addition, it decided in Pfizer's favor on a cross-appeal of the amount of bond the company is obligated to post in the case. The determination of bond was remanded to the district court with instructions to reduce the $15 million it...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.